British Journal of Cancer published a clinical update in Oncology on 08 Apr 2026.
The item focuses on Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Review the original article for the full source wording and details.